Expertise in
6
conditions

Takashi Iwata

Amagasaki, JP 
Expertise in
6
conditions
Amagasaki, JP 

Overview

Takashi Iwata practices practicing medicine in Amagasaki, Japan.

Mr. Iwata is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection, Hysterectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 190 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Amagasaki, Japan
Other Locations
Tokyo, Japan
Nagakute, Japan
Shinjiku, Japan
Shinjuku, Japan
Japan
Kobe, Japan
Tokushima, Japan
Okazaki, Japan
Kashiwa, 2778564, Japan
Keio, Japan
Asahimachi, 5458585, Japan
Shinjuku Ku, Japan. Department Of Otolaryngology Head And Neck Surgery, Kamigyo Ku, Kyoto, Japan
Tsu, 5148507, Japan
Miemachi, Japan
Osaka, Japan
Asahi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 24, 2026
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Study Phase: Phase 3
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: June 23, 2022
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

190 Total Publications

Endothelial protein C receptor expression as a marker of reduced metastatic risk in primary melanoma.
Endothelial protein C receptor expression as a marker of reduced metastatic risk in primary melanoma.
Journal: Melanoma research
Published: June 02, 2026

Frequently Asked Questions about Takashi Iwata

Is Takashi Iwata a top-rated expert for Cervical Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Takashi Iwata is classified as an Distinguished expert for Cervical Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Takashi Iwata participate in research or clinical trials?

Yes. Takashi Iwata has published 190 articles and abstracts on conditions like Cervical Cancer. You can view a list of Takashi Iwata's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Iwata's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile